OncoDaily Pulse

Aug 23, 2025, 12:27

Axel Bex: Meet the Experts of VIRO 2025

The Global Voices in Renal Oncology (VIRO) Virtual Congress, organized by OncoDaily, will be held on September 11–12, 2025. Chaired by Dr. Rana R. McKay with co-chair Dr. Yüksel Ürün, this year’s program will feature around 50 leading experts in renal oncology from across the globe, sharing cutting-edge updates and future perspectives.

The congress is free to attend.
Register here: https://forms.gle/qcQyaGMQfHDhanfD9

Co-Chair of VIRO

Images Name

Rana McKay
Professor of Medicine and Urology at UC San Diego Health Co-leader of the GU Oncology Program at Moores Cancer Center

As Co-Chair of VIRO, Dr. Rana McKay (University of California, San Diego) opened the congress with her talk on
“Future Directions: Emerging Agents and Combinations.”

She emphasized the momentum in renal cell carcinoma (RCC) research, highlighting how novel immunotherapies, targeted drugs, and rational combination strategies are reshaping patient care. Dr. McKay underscored the importance of personalized, biomarker-driven approaches and global collaboration, aiming to optimize survival and quality of life worldwide.

Spotlight on Axel Bex

Dr. Axel Bex is a Professor of Urology at the University of Amsterdam and a Consultant Urologist at The Royal Free London NHS Foundation Trust. He is internationally recognized for his expertise in renal cancer surgery and translational research, with a focus on integrating systemic therapy into the management of localized and locally advanced renal cell carcinoma.

At the Global Voices in Renal Oncology (VIRO) Virtual Congress 2025, Dr. Bex will present on “Neoadjuvant Therapy: Current Evidence and Ongoing Trials, Risk Stratification and Perioperative Management for Localized Disease” in the session on localized RCC. His lecture will provide an in-depth overview of how novel perioperative strategies are shaping clinical practice in kidney cancer.

Dr. Bex will discuss

The latest clinical evidence on neoadjuvant systemic therapies in localized RCC.
How risk stratification tools guide patient selection and treatment sequencing.
Perioperative management strategies to optimize surgical outcomes.

Ongoing clinical trials that aim to refine the role of neoadjuvant and adjuvant therapies.

By addressing both evidence and evolving practices, Dr. Bex highlights the critical intersection of surgery and systemic therapy in RCC. His work emphasizes the importance of precision approaches and collaborative research in advancing outcomes for patients with localized renal cancer.